1. S144: IMMUNE RESTORATION AND SYNERGISTIC ACTIVITY WITH FIRST-LINE (1L) IBRUTINIB (IBR) PLUS VENETOCLAX (VEN): TRANSLATIONAL ANALYSES OF CAPTIVATE PATIENTS WITH CLL. (23rd June 2022) Authors: Solman, I.; Singh Mali, R.; Scarfo, L.; Choi, M.; Moreno, C.; Grigg, A.; Dean, J. P.; Szafer-Glusman, E. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 45 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. UMBRALISIB MONOTHERAPY DEMONSTRATES EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA: A MULTICENTER, OPEN‐LABEL, REGISTRATION DIRECTED PHASE 2 STUDY. (12th June 2019) Authors: Zinzani, P.; Samaniego, F.; Jurczak, W.; Lech‐Maranda, E.; Ghosh, N.; Anz, B.; Patten, P.; Reeves, J.; Leslie, L.A.; Smolewski, P.; Chavez, J.C.; Scarfo, L.; Derenzini, E.; Burke, J.M.; Sharman, J.; Kolibaba, K.; O'Connor, O.A.; Cheah, C.Y.; Miskin, H.P.; Sportelli, P. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 182 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗